Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in eae

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Kovalchin, Joseph ^a   Krieger, Jeffrey ^a   Genova, Michelle ^a   Kawamoto, Norio ^b   Augustyniak, Michael ^a   Collins, Kathryn ^a   Bloom, Troy ^a   Masci, Allyson ^a   Hittinger, Tara ^a   Dufour, Ingrid ^a   Strominger, Jack L ^b   Zanelli, Eric ^a  

^a Peptimmune Inc   (United States)

^b Harvard University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID COPOLYMER; AMINO ACID COPOLYMER YFAK; CXCL1 CHEMOKINE; CXCL13 CHEMOKINE; CXCL2 CHEMOKINE; GLATIRAMER; INTERLEUKIN 12P70; INTERLEUKIN 3; INTERLEUKIN 6; MACROPHAGE DERIVED CHEMOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AMINO ACID; CCL22 PROTEIN, MOUSE; CHEMOKINE; CXCL13 PROTEIN, MOUSE; HLA ANTIGEN CLASS 2; PEPTIDE;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG BLOOD LEVEL; IN VITRO STUDY; INNATE IMMUNITY; MACROPHAGE; MALE; MOUSE; NONHUMAN; SPLEEN CELL; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; CELL LINE; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; KINETICS; MOLECULAR GENETICS; PATHOLOGY; SECRETION; SPLEEN;

AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; BONE MARROW CELLS; CELL LINE; CHEMOKINE CCL22; CHEMOKINE CXCL13; CHEMOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNITY, INNATE; INTERLEUKIN-3; KINETICS; MACROPHAGES; MALE; MICE; MOLECULAR SEQUENCE DATA; ORGAN SPECIFICITY; PEPTIDES; SPLEEN;

EID: 83455205820     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026274     Document Type: Article

References (40)

1. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M, (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1: 242-8.
2. Teitelbaum D, Webb C, Bree M, Meshorer A, Arnon R, Sela M, (2005) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1 (4): 242-248.
3. Fridkis-Hareli M, Santambrogio L, Stern JN, Fugger L, Brosnan C, et al. (2002) Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis. J Clin Invest 109: 1635-43.
4. Stern JN, Illés Z, Reddy J, Keskin DB, Sheu E, et al. (2004) Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms. Proc Natl Acad Sci USA 101: 11743-8.
5. Illés Z, Stern JN, Reddy J, Waldner H, Mycko MP, et al. (2004) Modified amino acid copolymers suppress myelin basic protein 85-99- induced encephalomyelitis in humanized mice through different effects on T cells. Proc Natl Acad Sci USA 101: 11749-54.
6. Stern JN, Keskin DB, Zhang H, Lv H, Kato Z, et al. (2008) Amino acid copolymer-specific IL-10-secreting regulatory T cells that ameliorate autoimmune diseases in mice. Proc Natl Acad Sci USA 105: 5172-6.
7. Yin H, Vistica BP, Chan CC, Strominger JL, Gery I, (2009) Inhibition of experimental autoimmune uveitis by amino acid copolymers. J Neuroimmunol 215 (1-2): 43-8.
8. Kovalchin J, Krieger J, Collins K, Genova M, Augustyniak M, et al. (2011) Safety, Pharmacokinetic, and Pharmacodynamic Evaluations of PI-2301, a Potent Immunomodulator, in a First-in-Human, Single-Ascending-Dose Study in Healthy Volunteers. J Clinical Pharma 51 (5): 649-60.
9. Kovalchin J, Krieger J, Genova M, Collins K, Augustyniak M, et al. (2010) Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response. J Neuroimmunol 225 (1-2): 153-63.
10. Hussien Y, Sanna A, Söderström M, Link H, Huang YM, (2001) Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol 121 (1-2): 102-10.
11. Vieira PL, Heystek HC, Wormmeester J, Wierenga EA, Kapsenberg ML, (2003) Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells. J Immunol 170: 4483-4488.
12. Kim HJ, Ifergan I, Antel JP, Seguin R, Duddy M, et al. (2004) Type 2 Monocyte and Microglia Differentiation Mediated by Glatiramer Acetate Therapy in Patients with Multiple Sclerosis. J Immunology 172: 7144-7153.
13. Weber MS, Prod'homme T, Youssef S, Dunn SE, Rundle CD, et al. (2007) Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 13: 935-43.
14. Kala M, Rhodes SN, Piao WH, Shi FD, Campagnolo DI, et al. (2010) B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol 221 (1): 136-45.
15. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, et al. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25 (12): 677-86.
16. Fridkis-Hareli M, Teitelbaum D, Gurevich E, Pecht I, Brautbar C, et al. (1994) Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells-specificity and promiscuity. Proc Natl Acad Sci USA 91 (11): 4872-6.
17. Fridkis-Hareli M, Strominger JL, (1998) Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immunol 160 (9): 4386-97.
18. Kuroda E, Ho V, Ruschmann J, Antignano F, Hamilton M, et al. (2009) SHIP represses the generation of IL-3-induced M2 macrophages by inhibiting IL-4 production from basophils. J Immunol 183 (6): 3652-60.
19. Makarenkova VP, Bansal V, Matta BM, Perez LA, Ochoa JB, (2006) CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol 176: 2085-94.
20. Li Q, Milo R, Panitch H, Swoveland P, Bever CT Jr, (1998) Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma. Eur J Pharmacol 342: 303-10.
21. Hohlfeld R, Wekerle H, (2004) Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci 101 (Suppl 2): 14599-606.
22. Racke MK, Lovett-Racke AE, Karandikar NJ, (2010) The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 74: S25-30.
23. Gordon S, Martinez FO, (2010) Alternative activation of macrophages: mechanism and functions. Immunity 32 (5): 593-604.
24. Jee Y, Piao WH, Liu R, Bai XF, Rhodes S, et al. (2007) CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. Clin Immunol 125: 34-42.
25. Venken K, Hellings N, Broekmans T, Hensen K, Rummens JL, et al. (2008) Natural naïve CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J Immunol 180: 6411-20.
26. Zhang H, Stern JN, Strominger JL, (2009) T cell receptors in an IL-10-secreting amino acid copolymer-specific regulatory T cell line that mediates bystander immunosuppression. Proc Natl Acad Sci USA 106: 3336-41.
27. Zhu B, Bando Y, Xiao S, Yang K, Anderson AC, et al. (2007) CD11b+Ly-6Chi suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 179: 5228-37.
28. Gabrilovich DI, Nagaraj S, (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-74.
29. Mantovani A, Sozzanic S, Locati M, Allavena P, Sica A, (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology 23 (11): 549-555.
30. Mohamadzadeh M, Poltorak AN, Bergstressor PR, Beutler B, Takashima A, (1996) Dendritic cells produce macrophage inflammatory protein-1 gamma, a new member of the CC chemokine family. J Immunol 156: 3102-6.
31. Sinha P, Clements VK, Ostrand-Rosenberg S, (2005) Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174: 636-45.
32. Aggarwal BB, Shishodia S, Takada Y, Jackson-Bernitsas D, Ahn KS, et al. (2006) TNF blockade: an inflammatory issue. Ernst Schering Res Found Workshop 56: 161-86.
33. Glabinksi AR, Bielecki B, Kawczak JA, Tuohy VK, Selmaj K, et al. (2004) Treatment with soluble tumor necrosis factor receptor (sTNFR):Fc/p80 fusion protein amerliorates relapsing-remitting experimental autoimmune encephalomyelitis and decreases chemokine expression. Autoimmunity 37: 465-71.
34. Sethi G, Sung B, Kunnumakkara AB, Aggarwal BB, (2009) Targeting TNF for treatment of cancer and autoimmunity. Adv Exp Med Biol 647: 37-51.
35. Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A, (2009) The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets 8: 40-52.
36. Wu C, Yang G, Bermúdez-Humarán LG, Pang Q, Zeng Y, et al. (2006) Immunomodulatory effects of IL-12 secreted by Lactococcus lactis on Th1/Th2 balance in ovalbumin (OVA)-induced asthma model mice. International Immunopharmacol 2006; 6: 610-5.
37. Mellergård J, Edström M, Vrethem M, Ernerudh J, Dahle C, (2010) Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler 16: 208-17.
38. Chen C, Liu X, Wan B, Zhang JZ, (2009) Regulatory properties of copolymer I in Th17 differentiation by altering STAT3 phosphorylation. J Immunol 183 (1): 246-53.
39. Scotton CJ, Martinez FO, Smelt MJ, Sironi M, Locati M, et al. (2005) Transcriptional profiling reveals complex regulation of the monocyte IL-1 beta system by IL-13. J Immunol 174 (2): 834-45.
40. Newcomb DC, Zhou W, Moore ML, Goleniewska K, Hershey GK, et al. (2009) A functional IL-13 receptor is expressed on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17 cytokine production. J Immunol 182 (9): 5317-21.